Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine
The long-running saga of Elan's (ELN) attempt to come up with a vaccine for Alzheimer's disease continues. There have been bold attempts, setbacks, rethinks, more setbacks, and now they're starting up again. Dosing of the latest version of their vaccine against the beta-amyloid protein, known as ACC-001, was suddenly halted in April when one patient came down with a skin lesion which was thought to be possibly autoimmune-linked vasculitis.
Biopsy results didn't confirm that, though, and the Elan/Wyeth (WYE) partnership is resuming clinical studies. I'm not sure what that couple of months has done to their trial design; I assume that they've just started enrolling new patients and will continue with them, while continuing to monitor the former dosage groups. Maybe, though, there's a way to continue with some of those people and not lose all the time, effort, and data.
The idea of an amyloid vaccine has always excited and alarmed me in equal measure. But that's how I feel about the immune system in general, come to think of it. We have enough cellular firepower to completely destroy ourselves from the inside out - keeping that on a leash to where it (mostly) only goes after what it's supposed to is extremely impressive.
Now, I think that the usual sorts of vaccines are one of the great public health advances of civilization, but they work so well because they're targeted to outside agents (viral coat proteins and the like). Even so, there's a disturbingly large part of the population that remain suspicious of all vaccinations - I say "disturbing" not least because if that population gets too large, the efficacy of vaccination in general could be crippled. But what will these people think about a vaccine that's targeted to an endogenous protein? My immunology may need brushing up, but I can't think of any other example of such.
One thing that may keep this from becoming a huge issue, though, is that an amyloid vaccine, if it succeeds, will be targeted at the elderly rather than at children. And it'll be something that will have an effect against a disease that everyone can see right in front of them, rather than preventing diseases that most people have only read about in books. We'll be back at the situation that prevailed when the polio vaccine was introduced: no one had much doubt that the vaccine was better than the disease.
But even a vaccine fan like me still has room to admire, from a distance, the nerve of this approach. The brain is a special case, immunologically, and letting slip the dogs of war in there is not an intrinsically safe idea. But Alzheimer's is an intrinsically nasty disease...
- 'When There's Blood in the Streets', Buy Biotech Stocks »
- Federal Circuit Affirms Merck’s Victory in Trusopt/Cosopt Case »
- Viropharma, Lev Pharmaceuticals: An Attractive Biotech Pair »
- Sequenom Down on Threat of Competition »
- Four Value Priced Stocks: Sysco, Eli Lilly, PepsiCo and Johnson & Johnson »
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- Apocalypse Dow: The Search for Scapegoats
- Reading the S&P 500's Crashing Waves
- On a Return to Normalcy: Dow 8,500
- Looking Back at Lehman: Lying, Scapegoating and a General Lack of Accountability
- iShares ETF Tracking Error: Risks and Explanations
- U.S. vs. the World: Sectors Matter
- Full list of Editor's Picks »
- Nation's Debt: It's Not Being Rescued, It's Being Moved Around »
- Crazy P/E Ratios »
- Clueless - Cramer's Mad Money (10/8/08) »
- Wall Street Breakfast: Must-Know News »
- Cramer: Dow Could Drop Another 14%, Oil's Going to $50 »
- Roger Wiegand: 'Severe Bull Market' Ahead for Gold »
- Awaiting Apple Earnings and Guidance »
- Four Ways to Protect Money During the Fallout »
- Ford, GM on the Chopping Block? »
- Earnings Preview: General Electric »
- Cramer Should Be Suspended »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Midstream MLPs Crashing, Present Opportunity
- A Fresh Look at Shipping Company Stocks
- Panic Selling in InterOil: What Now?
- Potash Corp.: No Liquidity Problems Here
- The Year of the Bear
- Cobalt: More Than Just Blue
- Investors Can Find Comfort in Big Blue
- Hershey: The Perfect Recession Investment?
- Applied Materials Leads by Example
- Full list of Long Ideas »
- The Short Case for General Electric
- Too Late to Short SPY? An Historical Perspective
- Henderson Group: Profit Warning Surprises Short Investors
- Decreasing Chipotle Traffic Could Spell Trouble
- Why I Sold Lowe's Short
- Accor, Host and Marriott: Short Interest Heats Up
- Global Financial Crisis Makes Oil a Great Hedge
- Michael Page International: Stock Down on Market Weakness
- Gaming Stocks Still a Poor Bet - Barron's
- After Coming Rate Cuts, Some Appealing Short ETFs
- Full list of Short Ideas »
- Clueless - Cramer's Mad Money (10/8/08)
- Torpedo Dry Ships - Cramer's Lightning Round (10/8/08)
- Chocolate Lover - Cramer's Mad Money (10/7/08)
- Yield is King - Cramer's Lightning Round (10/7/08)
- Goldman Disses Solar - Cramer's Stop Trading ! (10/7/08)
- Time to Hoard Cash - Cramer's Mad Money (10/6/08)
- Buyers On Strike - Cramer's Stop Trading! (10/6/08)
- Still Bullish on RIMM - Cramer's Lightning Round (10/6/08)
- The Cramer Crash?
- Cramer: Dow Could Drop Another 14%, Oil's Going to $50
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »



This article has 6 comments:
The brain, as I'm sure you know, is an "immuno-privilege... site-- that is, normally immune cells never enter the brain unless explicitly instructed to do so (e.g. with a vaccine). Leukocytes are not "trained" not to react to brain antigens they way they are with almost every other antigen in the body so the brain doesn't become the accidental target of damaging inflammation. Any sort of vaccine could induce that vaccination-- ACN-1792 was stopped in its tracks in pIIa because of that very inflammation problem.
Elan is all excited because, even though their active vaccination didn't show much in the way of cognitive improvement, iautopsies of dead patients pII trials showed plaque regression. However, replacing one neurological disease with another isn't ideal and would probably only be OK'd for extreme cases. I am unimpressed.
The passive vaccination (AB-001) is safer, and indeed it seems to work better (even though in my opinion it's still risky). Nonetheless, passive immunization is not nearly as sexy as an active immunization that could work prophylactically to cure Alzheimers like we cured Polio. The word "vaccine" has people all excited when perhaps they shouldn't be.
Even passive immunization to beta-amyloid, though, vaguely misses the mark. It doesn't nip the problem in the bud. A secretase inhibitor-- something in Elan's pipeline-- would be able to nip the problem in the bud. However, it's years and years away...
I'm intrigued and think that perhaps I will write up a full review of immunotherapies for Alzheimer disease... bestofbiotech.wordpres...
Replace "vaccination"... with "inflammation.&qu... My bad.